Completed PHASE2 INTERVENTIONAL NCT00005974

Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma

Sponsor: NCIC Clinical Trials Group

Conditions Sarcoma

Interventions alvocidib

Updated 9 times since 2017 Last updated: Apr 7, 2020 Started: Jul 4, 2000 Primary completion: Nov 7, 2002 Completion: Sep 22, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Sarcoma, this trial is completed. The trial is conducted by NCIC Clinical Trials Group and has accumulated 9 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Apr 2020 — May 2020 [monthly]

Completed PHASE2
Mar 2020 — Apr 2020 [monthly]

Completed PHASE2
Jun 2018 — Mar 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NCIC Clinical Trials Group

Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barrie, Canada , Brampton, Canada , Burnaby, Canada , Calgary, Canada , Charlottetown, Canada , Duluth, United States , Fleurimont, Canada , Greater Sudbury, Canada , Greenfield Park, Canada , Halifax, Canada and 34 more locations